Chloramphenicol and Oxazolidinones

Correct Answer

B — Chloramphenicol

Rationale

Chloramphenicol is the sole clinically used agent in its antibiotic class. Linezolid is an oxazolidinone. Doxycycline is a tetracycline. Azithromycin is a macrolide. Recognizing chloramphenicol as its own distinct antibiotic class is the task here.

Correct Answer

D — First-generation oxazolidinone

Rationale

Linezolid is the first-generation oxazolidinone, approved in 2000 as the first agent in this class. Tedizolid, approved in 2014, is the second-generation oxazolidinone. There is no third-generation agent currently in clinical use, and glycylcycline is a tetracycline subclass — not an oxazolidinone. Knowing linezolid's generational classification within the oxazolidinone class is the task here.

Correct Answer

A — Second-generation oxazolidinone

Rationale

Tedizolid is the second-generation oxazolidinone, approved in 2014, following linezolid as the first-generation agent approved in 2000. There is no third-generation oxazolidinone currently in clinical use. Glycylcycline is a tetracycline subclass (tigecycline) entirely separate from the oxazolidinones. Knowing tedizolid's generational classification within the oxazolidinone class is the task here.

Correct Answer

C — Linezolid

Rationale

Linezolid is an oxazolidinone antibiotic. Chloramphenicol is its own separate antibiotic class. Doxycycline is a tetracycline. Vancomycin is a glycopeptide. Recognizing linezolid as the oxazolidinone among agents from other antibiotic classes is the task here.

Correct Answer

B — Reversible nonselective monoamine oxidase inhibitor

Rationale

Linezolid is classified as a reversible, nonselective monoamine oxidase inhibitor — a pharmacological property that is entirely separate from its antibiotic mechanism and has significant drug interaction implications. Monoamine oxidase enzymes in neurons and the gut metabolize serotonin, dopamine, and norepinephrine. When linezolid inhibits these enzymes, serotonin accumulates, creating risk of serotonin syndrome if serotonergic drugs are co-administered. This dual classification — oxazolidinone antibiotic and monoamine oxidase inhibitor — is what makes prescribing linezolid in patients on antidepressants particularly hazardous. Cytochrome P450 3A4 inhibition is associated with macrolides (erythromycin, clarithromycin). Cytochrome P450 2C19 inhibition is associated with chloramphenicol. Acetylcholinesterase inhibition is the mechanism of organophosphates and certain dementia medications.

Correct Answer

A — Cytochrome P450 2C19

Rationale

Chloramphenicol is classified as a cytochrome P450 2C19 inhibitor. This enzyme inhibitory classification is a key feature that distinguishes chloramphenicol's drug interaction profile from other antibiotic classes. Cytochrome P450 3A4 inhibition characterizes erythromycin and clarithromycin. Cytochrome P450 1A2 inhibition characterizes ciprofloxacin. Cytochrome P450 2D6 inhibition characterizes fluoxetine and other agents, not chloramphenicol. Knowing chloramphenicol's CYP enzyme inhibitory classification is the task here.

Correct Answer

C — Chloramphenicol is bactericidal against Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae at clinical concentrations, despite being bacteriostatic against most other organisms

Rationale

Chloramphenicol is classified as bacteriostatic because its reversible binding to the 50S ribosomal subunit halts protein synthesis without killing most organisms. However, at clinically achievable concentrations, it is bactericidal specifically against the three principal bacterial causes of meningitis — Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae. This exception is clinically relevant because meningitis requires bactericidal drug activity in the cerebrospinal fluid for reliable cure. The bactericidal activity against these three organisms, combined with its exceptional cerebrospinal fluid penetration, is the pharmacological basis for chloramphenicol's historical and continued use in bacterial meningitis when beta-lactams cannot be used. Chloramphenicol is not bactericidal against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, or all anaerobes.

Correct Answer

A — Immature hepatic glucuronidation in neonates prevents chloramphenicol inactivation, causing drug accumulation; elevated plasma concentrations inhibit mitochondrial protein synthesis in cardiac muscle, producing myocardial depression and cardiovascular collapse

Rationale

Gray baby syndrome occurs because of a pharmacokinetic mismatch, not intrinsic neonatal sensitivity. Chloramphenicol is metabolized primarily by hepatic glucuronidation — a pathway that is substantially underdeveloped in neonates, particularly premature infants. When doses appropriate for older patients are given, chloramphenicol cannot be conjugated at an adequate rate, accumulates to toxic plasma concentrations, and inhibits mitochondrial protein synthesis in cardiac and skeletal muscle. Mitochondria use ribosomes structurally similar to bacterial 70S ribosomes, making them susceptible to chloramphenicol. The resulting myocardial depression causes cardiovascular collapse with the characteristic ashen-gray skin appearance from poor perfusion. The problem is eliminated by using substantially lower neonatal doses with serum level monitoring, targeting peak concentrations below 25 micrograms per milliliter. Renal excretion, calcium channel blockade, and protein binding operate through distinct pathways unrelated to the glucuronidation failure that drives this syndrome.

Correct Answer

D — The first is dose-dependent, reversible myelosuppression from mitochondrial inhibition that can be predicted by serum level monitoring; the second is idiosyncratic, irreversible aplastic anemia unrelated to dose or plasma concentration that serum monitoring cannot prevent

Rationale

Chloramphenicol produces two entirely different bone marrow toxicities that must not be confused. The first is dose-dependent, reversible suppression of all three hematopoietic cell lines through inhibition of mitochondrial protein synthesis in bone marrow precursors. It occurs predictably when plasma concentrations exceed approximately 25 micrograms per milliliter, is detectable by monitoring, and reverses fully when the drug is stopped. The second is an idiosyncratic, irreversible aplastic anemia occurring at a rate of approximately 1 in 25,000 to 40,000 courses, unrelated to dose or plasma concentration, caused by toxic effects of drug metabolites on hematopoietic stem cells, and typically presenting weeks to months after drug exposure. Mortality exceeds 50% without transplantation. Serum level monitoring is useful for the first type and has no impact on the second. This distinction is the pharmacological basis for the restriction of systemic chloramphenicol use — the idiosyncratic aplastic anemia cannot be avoided by any monitoring strategy.

Correct Answer

B — Most beta-lactams require inflamed meninges to achieve adequate central nervous system concentrations; chloramphenicol reaches therapeutic cerebrospinal fluid levels even in early infection before significant inflammation develops, giving it a pharmacokinetic advantage for meningitis treatment when beta-lactams cannot be used

Rationale

Beta-lactam antibiotics cross the blood-brain barrier poorly under normal conditions because of active drug efflux and limited lipid solubility; their central nervous system penetration increases substantially only when meningeal inflammation disrupts the blood-brain barrier. Chloramphenicol is highly lipophilic and distributes freely into the central nervous system, achieving cerebrospinal fluid concentrations of 30 to 50% of simultaneous plasma levels even without meningeal inflammation. This penetration is clinically superior to most beta-lactams and is the pharmacokinetic basis for chloramphenicol's retained role in bacterial meningitis for patients who cannot receive beta-lactam therapy. Combined with its bactericidal activity against the three principal meningeal pathogens at clinical concentrations, chloramphenicol remains a viable alternative when no safer agent can be used. Standard intravenous dosing achieves adequate cerebrospinal fluid concentrations without intrathecal administration.

Correct Answer

A — Linezolid blocks assembly of the 70S initiation complex before translation begins; chloramphenicol inhibits the peptidyl transferase center during the elongation phase after the initiation complex has assembled

Rationale

Both linezolid and chloramphenicol target the 50S ribosomal subunit, but at distinct sites and at different phases of protein synthesis. Chloramphenicol binds the peptidyl transferase center during the elongation phase — after the 70S initiation complex has already assembled — and blocks the formation of new peptide bonds. Linezolid binds the 50S subunit at a separate site and prevents the 30S and 50S subunits from coming together to form the 70S initiation complex in the first place, blocking translation before elongation can begin. This pre-initiation mechanism is unique among clinical ribosomal inhibitors. Because the two drugs bind the 50S subunit at different sites, ribosomal modification resistance to chloramphenicol does not necessarily confer resistance to linezolid. The two drugs should not be combined because overlap of their 50S binding regions may produce pharmacodynamic antagonism.

Correct Answer

C — Linezolid has approximately 100% oral bioavailability, so the same dose given orally produces identical plasma drug exposure to the intravenous formulation, with no dose adjustment needed

Rationale

Linezolid's oral bioavailability of approximately 100% makes it one of the rare antibiotics where oral and intravenous formulations are completely interchangeable at the same dose. When a patient receiving intravenous linezolid can tolerate oral intake, the switch to oral therapy can be made immediately without any dose adjustment — the plasma drug exposure is identical. This property has meaningful clinical implications: it eliminates the need for continued intravenous access, reduces cost, and enables earlier hospital discharge. Vancomycin, the primary alternative for methicillin-resistant Staphylococcus aureus bacteremia, has no oral bioavailability and must be administered intravenously for bloodstream infections throughout the entire treatment course. The 68-hour tissue half-life describes azithromycin, not linezolid. Linezolid is not a prodrug, and its elimination does not primarily depend on renal function.

Correct Answer

D — Linezolid inhibits monoamine oxidase and sertraline blocks serotonin reuptake, together causing serotonin accumulation and serotonin syndrome

Rationale

Linezolid is a reversible, nonselective monoamine oxidase inhibitor — monoamine oxidase normally degrades serotonin. Sertraline is a selective serotonin reuptake inhibitor that prevents serotonin clearance from the synapse. When both pathways are blocked simultaneously, serotonin accumulates to toxic concentrations, producing serotonin syndrome: mental status changes, autonomic instability, and neuromuscular abnormalities. This drug combination is contraindicated. Linezolid does not inhibit cytochrome P450 3A4, and the interaction is pharmacodynamic, not pharmacokinetic or ribosomal.

Correct Answer

B — Linezolid inhibits mitochondrial protein synthesis in bone marrow precursors; thrombocytopenia is the most consistently observed hematologic manifestation

Rationale

Linezolid causes dose- and duration-dependent myelosuppression through inhibition of mitochondrial protein synthesis in bone marrow precursor cells — mitochondria have 70S ribosomes structurally similar to bacterial ribosomes and are susceptible to the drug. All hematopoietic cell lines are affected, but thrombocytopenia is the most consistently observed and typically appears after 10 to 14 days of therapy. Anemia and neutropenia can also develop with prolonged courses. The myelosuppression is fully reversible on stopping the drug. Weekly complete blood count monitoring is recommended for any course exceeding two weeks. This differs from chloramphenicol's idiosyncratic aplastic anemia, which is dose-independent, unpredictable, and irreversible.

Correct Answer

D — Neonatal hepatic glucuronidation is immature, so chloramphenicol accumulates to toxic plasma concentrations; elevated levels inhibit mitochondrial protein synthesis in cardiac muscle, producing myocardial depression, cardiovascular collapse, and the characteristic ashen-gray appearance

Rationale

Gray baby syndrome results from a pharmacokinetic failure specific to neonates. Chloramphenicol is normally inactivated in the liver by glucuronidation — conjugation to an inactive glucuronide for renal excretion. In neonates, particularly those born at or near term, the hepatic glucuronosyltransferase system is not yet mature and cannot process chloramphenicol at an adequate rate. Drug accumulates to toxic plasma concentrations when doses appropriate for older children are used. At elevated concentrations, chloramphenicol inhibits mitochondrial protein synthesis — mitochondria harbor 70S ribosomes susceptible to the drug — in cardiac and skeletal muscle, producing a direct myocardial depressant effect, cardiovascular collapse, and the ashen-gray skin discoloration from circulatory failure. The syndrome is entirely pharmacokinetic in origin, not idiosyncratic, and can be prevented by using appropriate neonatal doses with serum level monitoring targeting peaks below 25 micrograms per milliliter.

Correct Answer

B — Chloramphenicol achieves cerebrospinal fluid concentrations of 30 to 50% of plasma even without meningeal inflammation and is bactericidal against Streptococcus pneumoniae at clinical concentrations — the two properties needed for meningitis treatment

Rationale

Two pharmacological properties make chloramphenicol suitable for bacterial meningitis when beta-lactams cannot be used. First, its lipophilicity and distribution characteristics allow it to cross the blood-brain barrier freely, achieving cerebrospinal fluid concentrations of 30 to 50% of simultaneous plasma concentrations even before significant meningeal inflammation develops. This degree of central nervous system penetration is superior to most beta-lactams under non-inflamed conditions. Second, despite being generally bacteriostatic, chloramphenicol is bactericidal against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae — the three principal causes of bacterial meningitis — at clinically achievable concentrations. Meningitis treatment requires both adequate central nervous system drug delivery and bactericidal activity; chloramphenicol satisfies both requirements for this patient's infection. Chloramphenicol works through ribosomal inhibition, not penicillin-binding protein inhibition, and its typical course is given multiple times daily, not once daily.

Correct Answer

A — Linezolid inhibits monoamine oxidase and escitalopram blocks serotonin reuptake; together these two mechanisms cause serotonin accumulation producing the classic triad of mental status changes, autonomic instability, and neuromuscular abnormalities

Rationale

Linezolid is a reversible, nonselective monoamine oxidase inhibitor that blocks serotonin degradation. Escitalopram is a selective serotonin reuptake inhibitor that blocks serotonin clearance from the synaptic cleft. When both pathways are blocked simultaneously, serotonin accumulates to toxic concentrations, producing serotonin syndrome — the triad seen here: mental status changes (agitation), autonomic instability (hyperthermia, diaphoresis, tachycardia), and neuromuscular abnormalities (clonus). This combination is contraindicated. Linezolid does not inhibit cytochrome P450 3A4 or 2D6, and the mechanism is pharmacodynamic serotonin excess, not mitochondrial neurotoxicity.

Correct Answer

C — Linezolid has approximately 100% oral bioavailability, meaning a given oral dose produces the same plasma drug exposure as the identical intravenous dose, so no dose adjustment is needed when switching routes

Rationale

Linezolid is one of a small number of antibiotics with near-complete oral bioavailability of approximately 100%. This means that virtually all of an oral dose is absorbed from the gastrointestinal tract and reaches systemic circulation, producing plasma drug concentrations nearly identical to those achieved with the same dose given intravenously. Because the pharmacokinetic profiles are equivalent, no dose adjustment is required when switching from intravenous to oral therapy — the transition is one-to-one. This property is clinically valuable: it allows immediate oral step-down the moment the patient can tolerate oral intake, eliminating the need for intravenous access, reducing cost, and enabling earlier discharge. The mechanism is straightforward absorption — linezolid does not undergo substantial first-pass hepatic metabolism, is not a prodrug activated in the gut, and does not rely on gastrointestinal tissue storage. This bioavailability property is what distinguishes linezolid from vancomycin, which has no oral bioavailability for systemic infections and cannot be switched to oral therapy for bacteremia or soft tissue infections requiring systemic exposure.